Alzheimer's News Today

Data from the A4 study, the first and largest to focus on people who have early signs of Alzheimer’s but no symptoms yet, are now available. https://buff.ly/46LA7Lu

Columnist Ray Burow remembers her recently passed mother-in-law, who remained loving and loved during her short-term memory loss. https://buff.ly/3LPVsJU

Experimental blarcamesine (Anavex 2-73) was able to slow cognitive and functional decline in early Alzheimer’s patients over a year, data show. https://buff.ly/4fqspdB

Zunveyl, a new oral mild-to-moderate Alzheimer's therapy, showed bioequivalence to galanotamine but fewer GI issues like nausea in studies. https://buff.ly/3YkGZ07

Columnist Ray Burow, reflecting on caregiving for her late mother, ponders if it's sometimes OK to lie to a person with Alzheimer's disease. https://buff.ly/3WG6MhZ

The use of Montelukast oral film was shown to improve cognition in patients with mild to moderate Alzheimer's in a Phase 2 clinical trial. https://buff.ly/4cYUZRM

The FDA granted regenerative medicine advanced therapy (RMAT) status to experimental cell therapy Lomecel-B for mild Alzheimer’s disease. https://buff.ly/4bMe6gh

Foralumab is an antibody being developed by Tiziana Life Sciences that's designed to block CD3, a protein on the surface of immune T-cells. https://buff.ly/4bMqopa

Eli Lilly's donanemab, now Kisunla, was approved by the U.S. Food and Drug Administration for patients with early symptomatic Alzheimer’s. https://buff.ly/3RSbxlG

The safety and efficacy of buntanetap therapy are comparable in early Alzheimer’s patients regardless of APOE4 status, per new trial data. https://buff.ly/3RKfXLo

With the high temperatures expected this summer, columnist Ray Burow recalls tips she used to help loved ones with dementia handle the heat. https://buff.ly/4cj7E1p

The Phase 2 study will further assess SNK01's safety and its efficacy in about 30 patients who'll receive it every three weeks up to a year. https://buff.ly/3zjccpO

A decision from the FDA on once-monthly maintenance dosing of Leqembi in early Alzheimer's is expected by Jan. 25, 2025. https://buff.ly/4baeBAI

An advisory committee to the U.S. Food and Drug Administration (FDA) unanimously voted in favor of donanemab for early Alzheimer's. https://buff.ly/3VqFzhx

Columnist Ray Burow can attest to the challenges that sandwich generation caregivers face, but says her children learned valuable lessons. https://buff.ly/3Vznxuz

There's many ways to help call attention to the estimated 47 million people globally with Alzheimer's disease or dementia. https://buff.ly/4c4sBfY

Buntanetap, a small molecule from Annovis Bio, improved cognitive function in people with mild Alzheimer’s with certain biomarkers. https://buff.ly/3yGD7M2

Otsuka is stopping the development of AVP-786, its experimental therapy to treat agitation in people with Alzheimer’s disease. https://buff.ly/3KenxK4

As a cancer survivor, columnist Ray Burow considers how her chemotherapy treatment compares to her late mother's experience with Alzheimer's. https://buff.ly/3UGicA8

Eisai has started a rolling application seeking U.S. FDA approval of an under-the-skin injection version of Leqembi for early Alzheimer’s. https://buff.ly/3QIIUqr

An FDA advisory committee will hold a June 10 meeting to review data on a clinical trial of potential Alzheimer's treatment donanemab. https://buff.ly/3QFHe1c

Elecsys Phospho-Tau 217, a blood-based test that can distinguish Alzheimer’s from other disorders, may enable an earlier disease diagnosis. https://buff.ly/4dnvN7N

BioXcel plans to test BXCL501 for treating agitation in Alzheimer’s disease dementia in patients in nursing and assisted living facilities. https://buff.ly/3Q77jpy

SNK01, an NK cell therapy by NKGen Biotech, appears safe and well tolerated and may be of cognitive benefit in Alzheimer’s disease. https://buff.ly/43X1Dnz

Taking on caregiving for a loved one with Alzheimer's can seem impossible, says columnist Ray Burow, but only until it's done. https://buff.ly/3vxWJkw

Eisai is seeking FDA approval of a monthly maintenance IV regimen of Leqembi for people with early Alzheimer’s disease. https://buff.ly/3xw0IhL

VY-TAU01, an investigational therapy to prevent tau tangles in Alzheimer’s, was well tolerated and showed promise in preclinical studies. https://buff.ly/3vn7QN5

Being a sole caregiver for a loved one with Alzheimer's is hard work, says columnist Ray Burow, but help and resources are available. https://buff.ly/4a8wWOP

Eli Lilly asked the FDA last year to approve donanemab, based on the TRAILBLAZER-ALZ 2 trial that showed it slowed cognitive decline. https://buff.ly/3Pvsyku

The FDA granted breakthrough device designation to a Quanterix test measuring p-Tau 217 as a predictor of Alzheimer's disease. https://buff.ly/3Tyr7Er